RE: RNS - CD4 draft results positive5 Oct 2022 09:18
Under the terms of the sale the Company will receive an immediate cash payment of approximately £1.1m for fixed assets and inventory, representing the book values of these assets. Furthermore, the Company expects to receive up to an additional £4.0m for the intellectual property, which includes capitalised research and development expenditure, contingent on the successful outcome of an ongoing clinical study in Kenya which is anticipated to conclude in the Autumn. It should be noted that the VISITECT® CD4 test is already fully commercialised,